TACR1 and Parkinson disease: These results agree with the reported effects of NK1R antagonist treatment, which protected dopaminergic neurons, preserved barrier integrity, reduced neuroinflammation, and significantly improved motor function in a rat model of early Parkinson’s disease [19].